Skip to main content
WAVERLEY PHARMA INC. logo

WAVERLEY PHARMA INC. — Investor Relations & Filings

Ticker · WAVE ISIN · CA94357L1058 LEI · 254900VT8CXPPV1G5Q51 TSXV Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2022-04-30 Regulatory Filings
Country CA Canada
Listing TSXV WAVE

About WAVERLEY PHARMA INC.

https://www.waverleypharma.com/

Waverley Pharma Inc. is a specialty biopharmaceutical company engaged in the research, development, and commercialization of safe, effective, and affordable therapeutics. The company primarily focuses on oncology, developing treatments such as poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer. Waverley Pharma commercializes its pharmaceutical products in markets including the United Kingdom, evidenced by successful tenders for drugs like Capecitabine with NHS Scotland. Furthermore, the company operates a retail pharmacy in the United States, integrating pharmaceutical innovation with direct patient service operations.

Recent filings

Filing Released Lang Actions
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 related to reporting issuers and participation fees, submitted to the Alberta Securities Commission. It includes a management certification by an officer (Chief Financial Officer) certifying the completeness and accuracy of the form. The content focuses on market values, trading periods, and fee calculations rather than financial performance or detailed financial statements. The document is primarily a regulatory form with officer certification and fee calculation, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance document with certification, not a full financial report or announcement of a report.
2022-04-30 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for Waverley Pharma Inc. for the year ended December 31, 2021. It contains detailed financial performance analysis, operational overview, forward-looking statements, and financial results with comparative figures for 2020 and 2021. The document references audited consolidated financial statements prepared under IFRS but does not itself contain the full financial statements. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The MD&A is a management report explaining financial results, business trends, and outlook, which fits the definition of Management Reports (MDA). It is not an Annual Report (10-K) because it lacks the full financial statements and other components typical of an annual report. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive analysis and data, not just an announcement. Therefore, the correct classification is Management Reports (MDA).
2022-04-30 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management Discussion and Analysis' (MD&A) and covers the three and six months ended June 30, 2021. It includes detailed financial performance analysis, operational highlights, and forward-looking statements. The text references condensed consolidated interim financial statements and audited consolidated financial statements, indicating it is a comprehensive interim report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is not a brief announcement or certification. The MD&A is a management report explaining financial results and business trends for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report (IR).
2021-08-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Waverley Pharma Inc. for the three and six months ended June 30, 2021. It contains detailed unaudited financial statements including statements of financial position, net loss and comprehensive loss, changes in equity, cash flows, and accompanying notes. The document references compliance with IAS 34 Interim Financial Reporting and explicitly states it is an interim report. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2021-08-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily an officer certification letter and does not contain actual financial data or the interim report itself. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3005 characters), and it is clearly a certification rather than a full interim report or financial statement.
2021-08-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2021. The document is primarily an officer certification letter and does not contain actual financial data or the interim report itself. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3007 characters) and it is a certification, not the report itself.
2021-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.